BETH SALAZAR: Open Payments
NPI 1023386562 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,034 in 52 payments from 13 companies in 2025. Trend: 2023 $2,484 · 2024 $2,552 · 2025 $2,034
Food & beverage: $2,034
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $843 |
| Organon LLC | 11 | $475 |
| Regeneron Healthcare Solutions, Inc. | 8 | $222 |
| Botanix SB Inc | 3 | $186 |
| Arcutis Biotherapeutics, Inc. | 4 | $68 |
| Lilly USA, LLC | 2 | $56 |
| ABBVIE INC. | 2 | $33 |
| Galderma Laboratories, L.P. | 2 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Incyte Corporation | 1 | $28 |
Products named: DUPIXENT, VTAMA, SOFDRA, Zoryve, TREMFYA, RINVOQ, NEMLUVIO, EBGLYSS.
Industry payments across GA — which companies pay providers there.
